
Author Correction: Targeting the incretin system in obesity and type 2 diabetes mellitus

Correction to: *Nature Reviews Endocrinology*
<https://doi.org/10.1038/s41574-024-00979-9>,
published online 17 April 2024

<https://doi.org/10.1038/s41574-024-00997-7>

Published online: 07 May 2024

 Check for updates

Saleem Ansari, Bernard Khoo & Tricia Tan 

In the version of the article initially published, in the “GLPIRAs and cardiorenal risk” section, the sentence now reading “A dedicated trial studying the effects of weekly 1 mg semaglutide on renal outcomes ...” originally read “2.4 mg semaglutide” and has now been amended in the HTML and PDF versions of the article.

© Springer Nature Limited 2024